Breaking Finance News

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to Hold in a report released on 5/23/2017.

Yesterday Corvus Pharmaceuticals Inc (NASDAQ:CRVS) traded 8.34% higher at $11.20. CRVS’s 50-day average is $12.18 and its two hundred day average is $12.73. The last stock close price is down 10.62% from the two hundred day average, compared with the S&P 500 Index which has increased 0.01% over the same period. Volume of trade was down over the average, with 71,021 shares of CRVS changing hands under the typical 88,517

See Chart Below

Corvus Pharmaceuticals Inc (NASDAQ:CRVS)

Corvus Pharmaceuticals Inc has with a one year low of $8.27 and a one year high of $22.14 and has a total market value of $0.

A total of 1 brokerage has issued a report on the stock. 0 equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, 0 firms rating the stock a hold, 0 analysts rating the company a underperform, and finally zero analysts rating the stock a sell with a average stock price target of $24.00.

General Information About Corvus Pharmaceuticals Inc (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.